Trial · NCT04246047
Adverse events446
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 446
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Thrombocytopenia | Blood and lymphatic system disorders | Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) | 167 | 242 | 501 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Daratumumab + Bor + Dex | 122 | 246 | 269 |
| other | Anaemia | Blood and lymphatic system disorders | Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) | 45 | 242 | 66 |
| other | Anaemia | Blood and lymphatic system disorders | Daratumumab + Bor + Dex | 64 | 246 | 110 |
| other | Neutropenia | Blood and lymphatic system disorders | Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) | 34 | 242 | 83 |
| other | Neutropenia | Blood and lymphatic system disorders | Daratumumab + Bor + Dex | 27 | 246 | 51 |
| other | Lymphopenia | Blood and lymphatic system disorders | Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) | 21 | 242 | 44 |
| other | Lymphopenia | Blood and lymphatic system disorders | Daratumumab + Bor + Dex | 23 | 246 | 38 |
| other | Leukopenia | Blood and lymphatic system disorders | Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) | 14 | 242 | 42 |
| other | Leukopenia | Blood and lymphatic system disorders | Daratumumab + Bor + Dex | 10 | 246 | 17 |
| other | Peripheral sensory neuropathy | Nervous system disorders | Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) | 61 | 242 | 81 |
| other | Peripheral sensory neuropathy | Nervous system disorders | Daratumumab + Bor + Dex | 51 | 246 | 68 |
| other | Neuropathy peripheral | Nervous system disorders | Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) | 50 | 242 | 59 |
| other | Neuropathy peripheral | Nervous system disorders | Daratumumab + Bor + Dex | 55 | 246 | 70 |
| other | Dizziness | Nervous system disorders | Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) | 21 | 242 | 24 |
| other | Dizziness | Nervous system disorders | Daratumumab + Bor + Dex | 19 | 246 | 20 |
| other | Headache | Nervous system disorders | Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) | 21 | 242 | 25 |
| other | Headache | Nervous system disorders | Daratumumab + Bor + Dex | 18 | 246 | 20 |
| other | Polyneuropathy | Nervous system disorders | Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) | 15 | 242 | 17 |
| other | Polyneuropathy | Nervous system disorders | Daratumumab + Bor + Dex | 13 | 246 | 14 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04246047/events